Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) | Apply Online

Frequently Asked Questions (FAQs): Strategic Partnering to Evaluate Cancer Signatures (SPECS II)

What is SPECS II?

SPECS II (Strategic Partnering to Evaluate Cancer Signatures) is a National Cancer Institute (NCI) funding opportunity focused on moving multi-analyte molecular "signatures" from research settings into real clinical use.

What is the main purpose of this funding opportunity?

The main purpose is to close the translation gap between comprehensive tumor molecular research and practical clinical tools by supporting rigorous evaluation of integrated molecular signatures that clinicians can trust and use in decision-making.

What does "multi-analyte molecular signatures" mean in this program?

In this context, multi-analyte molecular signatures refer to tumor profiling approaches that analyze DNA, RNA, and protein-level alterations together, rather than looking at a single molecular layer in isolation.

Why does SPECS II emphasize analyzing DNA, RNA, and protein together?

The program is built on evidence that more complete tumor profiling can be achieved by integrating DNA, RNA, and protein data, and that these integrated signatures can correlate with meaningful clinical features such as prognosis, likely treatment response, or other patient-relevant outcomes.

Is this program focused on discovering new biomarkers?

No. The opportunity is not framed as basic discovery of new biomarkers in isolation. It is aimed at clinical application and evaluation, including careful testing of performance, reproducibility, implementability, and positioning for use in trials and eventual routine care.

What types of clinical relevance are expected for the molecular signatures?

The FOA highlights signatures that correlate with clinically meaningful features, including prognosis, likely treatment response, or other patient-relevant outcomes in cancer.

What does SPECS II mean by "translation"?

Translation here means turning complex molecular data into practical tools that can be used reliably in clinical settings, including evidence that a signature performs well, is reproducible, and can be implemented in a way that supports clinical decision-making.

What is meant by "strategic partnering" in SPECS II?

Strategic partnering refers to assembling multidisciplinary collaborations that collectively have the expertise and infrastructure needed to evaluate whether molecular signatures genuinely improve patient care.

What kinds of expertise are encouraged on SPECS II teams?

The FOA explicitly encourages teams that can span multiple domains, such as biospecimen acquisition and quality control, high-throughput molecular assays across DNA/RNA/protein, bioinformatics and statistical modeling, clinical oncology, pathology, trial design, and regulatory or commercialization planning.

What outputs does SPECS II expect funded projects to produce for the broader community?

A major goal is community impact through openly useful outputs. The FOA highlights publications and data sets that will be made available and accessible to the broader scientific community, aiming to create well-annotated, high-quality resources others can use.

How are the expected datasets intended to be used by other researchers?

The expectation is that curated publications, datasets, and methods will help others design future clinical trials, including trials that incorporate molecular signatures as stratification factors, eligibility criteria, or endpoints, and will reduce duplication by enabling others to learn from high-quality shared resources.

Does SPECS II require open access to data and publications?

The FOA emphasizes making publications and datasets available and accessible to the broader scientific community, indicating an expectation of sharing high-quality, well-annotated outputs.

Is commercialization allowed or encouraged under SPECS II?

Yes. The announcement encourages appropriate commercialization in ways that benefit public health. Commercialization is not presented as the primary purpose, but it is treated as a legitimate and sometimes necessary bridge to developing a robust, deployable test that can support real-world clinical adoption.

What kinds of commercialization-related activities are implied by the FOA?

The FOA suggests that real-world impact may require developing a standardized assay and analytical pipeline and, where appropriate, partnerships that support scaling, manufacturing, quality systems, and clinical adoption.

What funding mechanism does SPECS II use?

SPECS II uses the NIH U01 cooperative agreement mechanism.

What does a U01 cooperative agreement imply for how the project is run?

A U01 typically means the project remains investigator-initiated in many respects but involves substantial NIH program involvement compared to a standard research grant. This aligns with programs where coordination, milestone-driven progress, data sharing expectations, and cross-site collaboration are important.

Is there a guaranteed number of awards?

No. The FOA states that awards depend on available funds and on receiving a sufficient number of highly meritorious applications, and it does not promise a fixed number of awards.

Is cost sharing or matching required?

No. The opportunity does not require cost sharing or matching.

What is the funding category and type for this opportunity?

The record lists this as discretionary funding and places it under health-related research and development.

What CFDA numbers are associated with SPECS II?

The opportunity is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research) and CFDA 93.395 (Cancer Treatment Research).

Who is eligible to apply?

Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), state governments, small businesses, and for-profit organizations other than small businesses.

Are federal agencies eligible to apply?

Yes. Eligibility includes eligible agencies of the federal government.

Are non-U.S. (foreign) organizations eligible to apply?

Yes. Eligibility extends to non-U.S. entities (foreign organizations), signaling openness to international participation when scientifically justified.

Are regional organizations eligible to apply?

Yes. The eligibility list includes regional organizations.

Where was the full announcement posted?

The full announcement was hosted on the NIH Grants Guide page associated with PAR-10-126.

What is the FOA identifier for this opportunity?

The FOA is identified as PAR-10-126.

When was the FOA posted?

The provided record indicates the FOA was posted on March 8, 2010.

What are the closing dates shown in the record?

The record indicates an original closing date of June 15, 2012, and also shows a current closing date listed as March 14, 2011, with the opportunity shown as archived in April 2011.

What does it mean that the opportunity is "archived"?

Based on the provided record, "archived" indicates the listing is no longer active as a current open opportunity, and the record shows archival timing (April 2011) alongside the historical dates displayed.

Who is the contact for access or linking issues?

NIH provided an Office of Extramural Research (OER) webmaster contact for access or linking issues related to the announcement page.

What kind of long-term impact is SPECS II trying to achieve?

The program is designed to support near-term outputs like validated approaches, publications, and shareable datasets, while enabling longer-term impact such as better-designed clinical trials, stronger validation studies, and viable routes for implementing tests that improve patient outcomes.